Lexaria Bioscience Corp. (NASDAQ: LEXX) announced the extension of its Material Transfer Agreement (MTA) with a pharmaceutical company, referred to as PharmaCO, originally signed on August 30, 2024. The agreement has been extended through December 31, 2026, to allow PharmaCO time to receive and review Lexaria's 2026 research and development results related to GLP-1 drugs. This extension keeps the temporary exclusive license active and enables further strategic planning discussions with PharmaCO's human clinical and business development teams.
The MTA was established to evaluate Lexaria's patented DehydraTECH technology in a pre-clinical setting. DehydraTECH is a drug delivery formulation and processing platform designed to improve oral drug absorption, reduce side effects, and enhance delivery across the blood-brain barrier. The extension underscores the potential of this technology in the rapidly growing GLP-1 market, which includes drugs for diabetes and obesity.
Over the past 12 months, Lexaria has advanced its GLP-1 development program with three key studies: Human Study #7, Animal Study #1, and Animal Study #2. All three studies are fully funded with existing corporate resources and are currently in process. Results are expected during the third and fourth quarters of 2026. These studies aim to provide comprehensive evidence to facilitate further collaboration and potential licensing of Lexaria's technology.
The extension of the MTA is significant for Lexaria as it maintains a partnership with a pharmaceutical company that has shown interest in the DehydraTECH platform. The continued collaboration could lead to future licensing agreements or joint development efforts, potentially accelerating the commercialization of GLP-1 therapies with improved oral bioavailability. For Lexaria, this represents a validation of its technology and a step toward monetizing its intellectual property.
Lexaria holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. The company operates a licensed in-house research laboratory and has repeatedly demonstrated DehydraTECH's ability to increase bio-absorption and reduce side effects in various drug classes. The ongoing studies are designed to provide the necessary data to support broader adoption of the technology in the pharmaceutical industry.
As the GLP-1 market continues to expand, innovations in oral delivery could offer significant advantages over injectable formulations, improving patient compliance and convenience. Lexaria's technology has the potential to address key challenges in oral peptide delivery, such as low bioavailability and gastrointestinal degradation. The outcomes of the current studies will be critical in determining the future trajectory of the partnership and the technology's commercial prospects.
For more information about Lexaria and its DehydraTECH technology, visit www.lexariabioscience.com.
